Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 70


Phase II clinical trial of paclitaxel loaded polymeric micelle in patients with advanced pancreatic cancer.

Saif MW, Podoltsev NA, Rubin MS, Figueroa JA, Lee MY, Kwon J, Rowen E, Yu J, Kerr RO.

Cancer Invest. 2010 Feb;28(2):186-94. doi: 10.3109/07357900903179591.


Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer.

Lee KS, Chung HC, Im SA, Park YH, Kim CS, Kim SB, Rha SY, Lee MY, Ro J.

Breast Cancer Res Treat. 2008 Mar;108(2):241-50. Epub 2007 May 3.


Phase 1/2 study of intravenous paclitaxel and oral cyclophosphamide in pretreated metastatic urothelial bladder cancer patients.

Di Lorenzo G, Montesarchio V, Autorino R, Bellelli T, Longo N, Imbimbo C, Morelli E, Giannarini G, Mirone V, De Placido S.

Cancer. 2009 Feb 1;115(3):517-23. doi: 10.1002/cncr.24055.


Second-line chemotherapy with biweekly paclitaxel after failure of fluoropyrimidine-based treatment in patients with advanced or recurrent gastric cancer: a report from the gastrointestinal oncology group of the Tokyo cooperative oncology group, TCOG GC-0501 trial.

Koizumi W, Akiya T, Sato A, Yamaguchi K, Sakuyama T, Nakayama N, Tanabe S, Higuchi K, Sasaki T, Sekikawa T; Tokyo Cooperative Oncology Group (TCOG GI Group).

Jpn J Clin Oncol. 2009 Nov;39(11):713-9. doi: 10.1093/jjco/hyp099. Epub 2009 Oct 6.


Multicenter phase II trial of weekly paclitaxel for advanced or metastatic breast cancer: the Saitama Breast Cancer Clinical Study Group (SBCCSG-01).

Sato K, Inoue K, Saito T, Kai T, Mihara H, Okubo K, Koh J, Mochizuki H, Tabei T; Saitama Breast Cancer Clinical Study Group.

Jpn J Clin Oncol. 2003 Aug;33(8):371-6.


Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines.

Gianni L, Munzone E, Capri G, Villani F, Spreafico C, Tarenzi E, Fulfaro F, Caraceni A, Martini C, Laffranchi A, et al.

J Natl Cancer Inst. 1995 Aug 2;87(15):1169-75.


Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer.

Seidman AD, Tiersten A, Hudis C, Gollub M, Barrett S, Yao TJ, Lepore J, Gilewski T, Currie V, Crown J, et al.

J Clin Oncol. 1995 Oct;13(10):2575-81.


A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.

Amadori D, Frassineti GL, Zoli W, Milandri C, Tienghi A, Ravaioli A, Gentile A, Salzano E.

Semin Oncol. 1996 Oct;23(5 Suppl 11):16-22.


Phase II study of a cremophor-free, polymeric micelle formulation of paclitaxel for patients with advanced urothelial cancer previously treated with gemcitabine and platinum.

Lee JL, Ahn JH, Park SH, Lim HY, Kwon JH, Ahn S, Song C, Hong JH, Kim CS, Ahn H.

Invest New Drugs. 2012 Oct;30(5):1984-90. doi: 10.1007/s10637-011-9757-7. Epub 2011 Oct 20.


A Phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors.

Ansell SM, Pitot HC, Burch PA, Kvols LK, Mahoney MR, Rubin J.

Cancer. 2001 Apr 15;91(8):1543-8.


Sequential therapy in advanced non-small-cell lung cancer with weekly paclitaxel followed by cisplatin-gemcitabine-vinorelbine. A phase II study.

Feliu J, Martin G, Lizón J, Chacón JI, Dorta J, de Castro J, Rodríguez A, Sánchez Heras B, Torrego JC, Espinosa E, González Barón M; Oncopaz Cooperative Group, Spain.

Ann Oncol. 2001 Oct;12(10):1369-74.


Paclitaxel and cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma.

Adamo V, Ferraro G, Pergolizzi S, Sergi C, Laudani A, Settineri N, Alafaci E, Scimone A, Spano F, Spitaleri G.

Oral Oncol. 2004 May;40(5):525-31.


Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study.

Penel N, Bui BN, Bay JO, Cupissol D, Ray-Coquard I, Piperno-Neumann S, Kerbrat P, Fournier C, Taieb S, Jimenez M, Isambert N, Peyrade F, Chevreau C, Bompas E, Brain EG, Blay JY.

J Clin Oncol. 2008 Nov 10;26(32):5269-74. doi: 10.1200/JCO.2008.17.3146. Epub 2008 Sep 22.


Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: phase I results.

Holmes FA, Valero V, Walters RS, Theriault RL, Booser DJ, Gibbs H, Fraschini G, Buzdar AU, Willey J, Frye D, Asmar L, Hortobagyi GN.

Ann Oncol. 1999 Apr;10(4):403-11.


Phase II trial of 3-h infusion of paclitaxel in patients with adenocarcinoma of endometrium: Japanese Multicenter Study Group.

Hirai Y, Hasumi K, Onose R, Kuramoto H, Kuzuya K, Hatae M, Ochiai K, Nozawa S, Noda K.

Gynecol Oncol. 2004 Aug;94(2):471-6.


Paclitaxel by 24- or 1-hour infusion n combination with carboplatin in advanced non-small cell lung cancer: the Fox Chase Cancer Center experience.

Langer CJ, Leighton JC, Comis RL, O'Dwyer PJ, McAleer CA, Bonjo CA, Engstrom PF, Litwin S, Johnson S, Ozols RF.

Semin Oncol. 1995 Aug;22(4 Suppl 9):18-29.


Cisplatin-epirubicin-paclitaxel weekly administration in advanced breast cancer: a phase I study of the Southern Italy Cooperative Oncology Group.

Frasci G, D'Aiuto G, Comella P, Apicella A, Thomas R, Capasso I, Di Bonito M, Cartenì G, Biglietto M, De Lucia L, Maiorino L, Piccolo S, Bianchi U, D'Aniello R, Lapenta L, Comella G.

Breast Cancer Res Treat. 1999 Aug;56(3):239-52.


Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer.

Rizvi NA, Riely GJ, Azzoli CG, Miller VA, Ng KK, Fiore J, Chia G, Brower M, Heelan R, Hawkins MJ, Kris MG.

J Clin Oncol. 2008 Feb 1;26(4):639-43. doi: 10.1200/JCO.2007.10.8605.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk